非瓣膜性房颤抗凝治疗研究进展  

Research Progress of Anticoagulation Therapy for Nonvalvular Atrial Fibrillation

作　　者：刘善萍 何贵新[2] 甲子永 冯雨菲 韦娟 詹玲君 

机构地区：[1]广西中医药大学,广西南宁530001 [2]广西中医药大学第一附属医院,广西南宁530023

出　　处：《大众科技》2023年第3期162-166,共5页Popular Science & Technology

摘　　要：非瓣膜性房颤患者卒中及全身性栓塞疾病发病率持续增高,抗凝治疗成为防治该病最主要的环节,对卒中及全身性栓塞的防治更是成为近年来国内外研究的热点。在传统抗凝治疗方案中,华法林一直被视为心源性卒中抗凝的二级用药,而阿司匹林则预防合并有冠心病的非瓣膜性患者发生不明原因卒中上疗效显著。随着抗凝药物的发展,新型口服抗凝药实力性地成为首要选择;左心耳封堵术改变了长期口服抗凝药物的现状并解除了来自左心耳的血栓风险;导管消融手术联合抗凝药物的治疗措施不仅能控制房颤症状,还能防治血栓并发症。The incidence rate of stroke and systemic embolism in patients with nonvalvular atrial fibrillation continues to increase.Anticoagulant therapy has become the most important link in the prevention and treatment of this disease,and the prevention and treatment of stroke and systemic embolism has become a hot research topic at home and abroad in recent years.In the traditional anticoagulation treatment scheme,warfarin has been regarded as the secondary anticoagulation drug for cardiogenic stroke,while aspirin has a significant effect in preventing nonvalvular patients with coronary heart disease from having unexplained stroke.With the development of anticoagulants,the strength of new oral anticoagulants has become the first choice;left atrial appendage occlusion has changed the status quo of long-term oral anticoagulants and relieved the risk of thrombus from left atrial appendage;the treatment of catheter ablation combined with anticoagulant drugs can not only control the symptoms of atrial fibrillation,but also prevent and treat thrombotic complications.

关 键 词：非瓣膜性房颤 口服抗凝药 左心耳封堵术 房颤导管消融 

分 类 号：R541[医药卫生—心血管疾病]